Literature DB >> 25693854

Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.

Yoshiro Naito1, Aya Fujii1, Hisashi Sawada1, Makiko Oboshi1, Toshihiro Iwasaku1, Yoshitaka Okuhara1, Daisuke Morisawa1, Akiyo Eguchi1, Shinichi Hirotani1, Tohru Masuyama1.   

Abstract

Iron accumulation is associated with the pathophysiology of chronic kidney disease (CKD). Renal fibrosis is a final common feature that contributes to the progression of CKD; however, little is known about the association between renal iron accumulation and renal interstitial fibrosis in CKD. Here we investigate the effects of iron chelation on renal interstitial fibrosis in a rat model of CKD. CKD was induced by 5/6 nephrectomy in Sprague-Dawley rats. At 8 weeks after operation, 5/6 nephrectomized rats were administered an oral iron chelator, deferasirox (DFX), in chow for 8 weeks. Other CKD rats were given a normal diet. Sham-operative rats given a normal diet served as a control. CKD rats exhibited hypertension, glomerulosclerosis and renal interstitial fibrosis. Iron chelation with DFX did not change hypertension and glomerulosclerosis; however, renal interstitial fibrosis was attenuated in CKD rats. Consistent with these findings, renal gene expression of collagen type III and transforming growth factor-β was increased in CKD rats compared with the controls, while iron chelation suppressed these increments. In addition, a decrease in vimentin along an increase in E-cadherin in renal gene expression was observed in CKD rats with iron chelation. CKD rats also showed increased CD68-positive cells in the kidney, whereas its increase was attenuated by iron deprivation. Similarly, increased renal gene expression of CD68, tumor necrosis factor-α and monocyte chemoattractant protein-1 was suppressed in CKD rats with iron chelation. Renal iron accumulation seems to be associated with renal interstitial fibrosis in a rat model of CKD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25693854     DOI: 10.1038/hr.2015.14

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  34 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.

Authors:  Nimrit Goraya; Jan Simoni; Chanhee Jo; Donald E Wesson
Journal:  Kidney Int       Date:  2011-08-31       Impact factor: 10.612

3.  Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation.

Authors:  Eduardo Molina-Jijón; Guillermo Zarco-Márquez; Omar Noel Medina-Campos; Zyanya Lucía Zataraín-Barrón; Rogelio Hernández-Pando; Enrique Pinzón; Rosa Marina Zavaleta; Edilia Tapia; José Pedraza-Chaverri
Journal:  Toxicology       Date:  2011-11-15       Impact factor: 4.221

4.  Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats.

Authors:  Yoshiro Naito; Shinichi Hirotani; Hisashi Sawada; Hirokuni Akahori; Takeshi Tsujino; Tohru Masuyama
Journal:  Hypertension       Date:  2011-01-24       Impact factor: 10.190

5.  Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing.

Authors:  D C Harris; C Tay; B J Nankivell
Journal:  Clin Exp Pharmacol Physiol       Date:  1994-02       Impact factor: 2.557

6.  Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury.

Authors:  B R Reddy; R A Kloner; K Przyklenk
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

7.  Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.

Authors:  Garth L Maker; Brian Siva; Kevin T Batty; Robert D Trengove; Paolo Ferrari; John K Olynyk
Journal:  Nephrology (Carlton)       Date:  2013-03       Impact factor: 2.506

8.  Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

Authors:  B Payson Oberg; Elizabeth McMenamin; F Lee Lucas; Ellen McMonagle; Jason Morrow; T Alp Ikizler; Jonathan Himmelfarb
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

9.  Iron accumulation in human chronic renal disease.

Authors:  B J Nankivell; R A Boadle; D C Harris
Journal:  Am J Kidney Dis       Date:  1992-12       Impact factor: 8.860

10.  Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model.

Authors:  Yoshiro Naito; Aya Fujii; Hisashi Sawada; Shinichi Hirotani; Toshihiro Iwasaku; Yoshitaka Okuhara; Akiyo Eguchi; Mitsumasa Ohyanagi; Takeshi Tsujino; Tohru Masuyama
Journal:  J Hypertens       Date:  2013-06       Impact factor: 4.844

View more
  16 in total

1.  Attenuation of hypertension and renal damage in renovascular hypertensive rats by iron restriction.

Authors:  Makiko Oboshi; Yoshiro Naito; Hisashi Sawada; Toshihiro Iwasaku; Yoshitaka Okuhara; Akiyo Eguchi; Shinichi Hirotani; Toshiaki Mano; Takeshi Tsujino; Tohru Masuyama
Journal:  Hypertens Res       Date:  2016-07-21       Impact factor: 3.872

2.  Possible therapeutic impact of the iron chelation on renal fibrosis.

Authors:  Kouichi Tamura; Kazushi Uneda; Kengo Azushima; Hiromichi Wakui; Kotaro Haruhara
Journal:  Hypertens Res       Date:  2015-04-16       Impact factor: 3.872

3.  Novel insights into renovascular hypertension and cardio-renal protection by iron restriction.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Hypertens Res       Date:  2016-09-08       Impact factor: 3.872

4.  Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease.

Authors:  Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin
Journal:  Kidney Int       Date:  2020-06-20       Impact factor: 10.612

5.  Acute and Chronic Iron Overloading Differentially Modulates the Expression of Cellular Iron-homeostatic Molecules in Normal Rat Kidney.

Authors:  Bassem Refaat; Abdelghany Hassan Abdelghany; Mohammad A BaSalamah; Mohamed El-Boshy; Jawwad Ahmad; Shakir Idris
Journal:  J Histochem Cytochem       Date:  2018-06-06       Impact factor: 2.479

6.  Influence of dietary iron intake restriction on the development of hypertension in weanling prehypertensive rats.

Authors:  Keisuke Okuno; Yoshiro Naito; Seiki Yasumura; Hisashi Sawada; Makiko Oboshi; Koichi Nishimura; Masanori Asakura; Masaharu Ishihara; Tohru Masuyama
Journal:  Heart Vessels       Date:  2018-02-07       Impact factor: 2.037

Review 7.  The Cross-Link between Ferroptosis and Kidney Diseases.

Authors:  Jingyu Wang; Yi Liu; Yaqing Wang; Li Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-03       Impact factor: 6.543

8.  Kidney tubule iron loading in experimental focal segmental glomerulosclerosis.

Authors:  Dorine W Swinkels; Bart Smeets; Rachel P L van Swelm; Sanne Beurskens; Henry Dijkman; Erwin T G Wiegerinck; Rian Roelofs; Frank Thévenod; Johan van der Vlag; Jack F M Wetzels
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

9.  Erythropoiesis-independent effects of iron in chronic kidney disease.

Authors:  Edwin Patino; Oleh Akchurin
Journal:  Pediatr Nephrol       Date:  2021-07-09       Impact factor: 3.651

Review 10.  Abnormal Iron and Lipid Metabolism Mediated Ferroptosis in Kidney Diseases and Its Therapeutic Potential.

Authors:  Xiaoqin Zhang; Xiaogang Li
Journal:  Metabolites       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.